Mutual of America Capital Management LLC Reduces Position in Eli Lilly and Company (NYSE:LLY)

Mutual of America Capital Management LLC lessened its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 3.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 93,949 shares of the company's stock after selling 2,900 shares during the quarter. Eli Lilly and Company comprises about 0.9% of Mutual of America Capital Management LLC's investment portfolio, making the stock its 13th biggest position. Mutual of America Capital Management LLC's holdings in Eli Lilly and Company were worth $77,593,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of LLY. Platform Technology Partners boosted its position in Eli Lilly and Company by 17.0% in the first quarter. Platform Technology Partners now owns 2,534 shares of the company's stock valued at $2,093,000 after buying an additional 369 shares in the last quarter. Arizona State Retirement System boosted its position in Eli Lilly and Company by 2.0% in the first quarter. Arizona State Retirement System now owns 239,561 shares of the company's stock valued at $197,856,000 after buying an additional 4,599 shares in the last quarter. Valued Wealth Advisors LLC boosted its position in Eli Lilly and Company by 14.4% in the first quarter. Valued Wealth Advisors LLC now owns 135 shares of the company's stock valued at $112,000 after buying an additional 17 shares in the last quarter. Mathes Company Inc. lifted its position in shares of Eli Lilly and Company by 68.8% during the first quarter. Mathes Company Inc. now owns 945 shares of the company's stock worth $780,000 after purchasing an additional 385 shares in the last quarter. Finally, Kathmere Capital Management LLC lifted its position in shares of Eli Lilly and Company by 2.4% during the first quarter. Kathmere Capital Management LLC now owns 4,249 shares of the company's stock worth $3,510,000 after purchasing an additional 101 shares in the last quarter. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Price Performance

Shares of LLY traded up $10.28 during mid-day trading on Friday, reaching $771.78. The company had a trading volume of 3,351,657 shares, compared to its average volume of 3,664,442. The company's 50 day simple moving average is $767.03 and its 200 day simple moving average is $800.02. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37. The company has a market capitalization of $731.45 billion, a price-to-earnings ratio of 62.80, a P/E/G ratio of 1.12 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). The firm had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The firm's revenue for the quarter was up 45.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.58 EPS. Analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be paid a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.78%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 48.82%.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on LLY. Erste Group Bank downgraded shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. Hsbc Global Res downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. UBS Group lowered their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Morgan Stanley reaffirmed an "overweight" rating and issued a $1,135.00 target price (up previously from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. Finally, Guggenheim upped their target price on shares of Eli Lilly and Company from $936.00 to $942.00 and gave the company a "buy" rating in a research note on Friday, July 11th. One research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $1,012.56.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.